Dr. Kathryn R. Wagner

Dr. Leung obtained her undergraduate degree in biochemical sciences from Harvard University. While attending medical school at Duke University, she completed a year-long research fellowship studying genetic markers of late-onset Alzheimer’s disease at the National Institute on Aging as part of the NIH Clinical Research Training Program. She completed her neurology residency and clinical neurophysiology fellowship at Stanford University Medical Center, and is currently a Ph.D. candidate in the graduate training program in clinical investigation at the Johns Hopkins Bloomberg School of Public Health. Dr. Leung joined the Center for Genetic Muscle Disorders at the Kennedy Krieger Institute as a translational research fellow in 2010 and was appointed to the faculty in 2014. Her clinic specializes in electromyography and the diagnosis and treatment of hereditary muscle diseases. Dr. Leung’s research focuses on the development of imaging biomarkers and outcome measures for muscle diseases. She is the principal investigator for a longitudinal cohort study of whole-body MRI in facioscapulohumeral muscular dystrophy. Dr. Leung is also a site principal investigator for the Ionis-DMPKRx trial, a phase Ib/IIa clinical trial of a novel RNA-based therapy for myotonic muscular dystrophy. Dr. Leung is rated as an Elite provider by MediFind in the treatment of Dysferlinopathy. Her top areas of expertise are Facioscapulohumeral Muscular Dystrophy (FSHD), Dysferlinopathy, Limb-Girdle Muscular Dystrophy Type 2I, and Limb-Girdle Muscular Dystrophy.

Cheryl Smith is a Neurologist in Alexandria, Virginia. Dr. Smith is rated as an Advanced provider by MediFind in the treatment of Dysferlinopathy. Her top areas of expertise are Myasthenia Gravis, Spinal and Bulbar Muscular Atrophy, Spinal Muscular Atrophy Type 3, and Spinal Muscular Atrophy (SMA).

Dr. Tom Crawford has been a member of the Department of Neurology since 1987. He is co-director of the MDA clinic for Neuromuscular Disorders and Neurologist for the Ataxia Telangiectasia Clinical Center at Johns Hopkins. His practice involves general child neurology with a principal interest in caring for children with neuromuscular, neuromotor, and ataxic disorders. Primary research interests involve the basic science and clinical characterization of two important neurologic disorders that affect children: Spinal Muscular Atrophy and Ataxia Telangiectasia. He is also actively involved in the Biology of neurofilaments by characterization of transgenic animal models. He is on the Medical and Scientific Advisory Boards of Families of Spinal Muscular Atrophy, and the Medical Advisory Committee for the Muscular Dystrophy Association. He is the Neurologist for the Ataxia Telangiectasia Clinical Center at Johns Hopkins, which has evaluated almost half of the known patients with this disorder in the United States. Additional specific clinical interests include evaluation and treatment of children with brachial plexus palsies. Dr. Crawford received his medical degree from the University of Southern California. He completed a pediatric internship and residency at the Pediatric Pavilion of the Los Angeles County / University of Southern California Medical Center, followed by a pediatric chief residency. He completed his training in Neurology with Special Qualification in Child Neurology at the Los Angeles Childrens Hospital. He then traveled east to the laboratory of Dr John Griffin at Johns Hopkins for a fellowship in Neuromuscular Disorders. Prior to medical training and Neurology residency, he majored in Psychology and Religion at Yale College. Dr. Crawford has published extensively and presented nationally and internationally. He has an active role in teaching medical students and residents in neurology. In addition, Dr. Crawford has special interest and experience in EMG studies of children and adults. Dr. Crawford is rated as a Distinguished provider by MediFind in the treatment of Dysferlinopathy. His top areas of expertise are Primary Lateral Sclerosis, Spinal Muscular Atrophy (SMA), Ataxia-Telangiectasia, and Spinal Muscular Atrophy Type 2.